Please assess the completion status of the following clinical trial:

Trial Title: Improving the Immune System With Human IL-7 Vaccine in Older Subjects Who Have Had Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
* INCLUSION CRITERIA:~* Adults over the age of 60~* Documentation of positive diagnosis for any of the following:~  * Non metastatic breast carcinoma following neo-adjuvant chemotherapy and appropriate surgery or following adjuvant radio / chemotherapy.~ * Stage II or III colon carcinoma following appropriate surgery and adjuvant chemotherapy or following appropriate neoadjuvant chemoradiation/surgery and adjuvant chemotherapy.~ * Stage II bladder carcinoma following neo-adjuvant chemotherapy and appropriate surgery or following adjuvant chemotherapy. Patients with recurrent tumors are not eligible.~ * Appropriate therapy for each disease must be consistent with the latest National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology available at the web site: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp~ * Completed cancer specific therapy (including surgery, radiotherapy and/or chemotherapy) a minimum of 4 weeks prior to entry. (Subjects with hormone receptor positive breast carcinoma maintained on hormonal therapy following chemotherapy and radiation are eligible).~* Completed cancer specific therapy at most 6 months prior to entry.~* Reasonable expectation that no chemotherapy will be given in the subsequent 6 months (Principal Investigators (PIs) discretion).~* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \< 3 times the upper limit of normal.~* Bilirubin \< 1.5.~* Absolute Neutrophil Count greater than l000 / mm(3).~* Platelet count greater than 75K.~* International normalized ratio (INR)/partial thromboplastin time (PTT) within 1.5 times upper limit of normal (Common Terminology Criteria in Adverse Events (CTCAE) 4.0 grade 1 abnormality is acceptable)~* Serum creatinine within 1.5 times upper limit of normal (CTCAE 4.0 grade 1 abnormality is acceptable)~* Creatine phosphokinase (CPK) within 2.5 times upper limit of normal (CTCAE 4.0 grade 1 abnormality is acceptable)~* Serum albumin greater or equal to 3g/dl (CTCAE 4.0 grade 1 abnormality is acceptable)~* Serum electrolytes within normal limits (CTCAE 4.0 grade 1 abnormality is acceptable)~* Karnofsky performance status greater or equal to 70%.~EXCLUSION CRITERIA FOR ALL PARTICIPANTS:~* Significant heart disease defined as:~  * Significant coronary arterial disease~ * myocardial infarction in the last 6 months, angina in the previous 3 months,~ * Troponin elevation at level of myocardial infarction as defined by the manufacturer~ * Ischemic changes on electrocardiogram (ECG)~ * Atrio-ventricular block greater than 1st degree, in absence of pacemaker,~ * Corrected QT interval (QTc) greater than 480ms (CTCAE 4.0 grade 1 abnormality is acceptable),~ * History of ventricular arrhythmia,~ * Left Ventricular Ejection Fraction below the institutional limit of normal,~* Positive serology for human T-lymphotropic viruses, type 1 (HTLV I), human immunodeficiency virus (HIV), hepatitis A, hepatitis B, or hepatitis C infection including a positive hepatitis B serology indicative of previous immunization (i.e. hepatitis B surface antibody (HBs Ab) positive and hepatitis B core antibody (HBc Ab) negative)~* History of autoimmune disease: patients with vitiligo or endocrine disease controlled by replacement therapy including, diabetes, thyroid and adrenal disease may be enrolled~* Patients requiring chronic immunosuppressive therapy (including corticosteroids) for any medical condition,~* Splenomegaly or history of proliferative hematologic disease~* Prior allogeneic hematopoietic stem cell transplantation or solid organ transplantation~* Inability or refusal to practice contraception during therapy (as physiologically relevant)~* History of medical or psychiatric disease which, in the view of the principal investigator, would preclude safe treatment~* Cognitive impairment~* Serious bleeding diathesis or those who are on therapeutic anticoagulation~* Previous exposure to Hepatitis A or B vaccines~Patients who received a tetanus and diphtheria (Td) or tetanus, diphtheria- acelluar, pertussis (Tdap) immunization in the previous 5 years,~* History of anaphylaxis or serious allergic reactions to previous administration of any of the vaccines~* Known hypersensitivity to any of the following: diphtheria toxoid, neomycin, polymixin B, streptomycin, 2 phenoxyethanol, formaldehyde, aluminum hydroxide, yeast~* Patients who had received one or more doses of the pneumococcal polysaccharide vaccine 23 (PPSV23) vaccine in the previous 12 months~* Inability to give informed consent

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Arm A -Sequence 1 Immunizations (Type: EXPERIMENTAL): Receive vaccine of Sequence 1 first, then vaccines of Sequence 2, 7 weeks later, after receiving interleukin-7 (IL-7)
- Arm B - Sequence 2 Immunizations (Type: EXPERIMENTAL): Receive vaccines of Sequence 2 first then vaccines of Sequence1, 7 weeks later, after receiving IL-7

Based on this trial design, predict the completion outcome and termination type (if applicable).